EyePoint (EYPT) Net Equity Issued and Repurchased (2011 - 2025)
EyePoint (EYPT) reported Net Equity Issued and Repurchased of $166.8 million for Q4 2025, up 10.08% on a YoY basis from $151.5 million in Q4 2024, and up 2317.2% sequentially from $6.9 million in Q3 2025.
EyePoint (EYPT) Net Equity Issued and Repurchased (2011 - 2025) Analysis & Trends
EyePoint (EYPT) has 13 years of Net Equity Issued and Repurchased data on file, last reported at $166.8 million in Q4 2025.
- For the quarter ending Q4 2025, Net Equity Issued and Repurchased rose 10.08% year-over-year to $166.8 million; the trailing twelve-month figure through Dec 2025 stood at $337.4 million (down 14.3% YoY), and the FY2025 full-year result was $173.4 million, up 6.2% from the prior year.
- Net Equity Issued and Repurchased grew to $166.8 million in Q4 2025, from $6.9 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $230.0 million in Q4 2023 to a low of -$7.3 million in Q3 2021.
- A 4-year average of $84.5 million and a median of $63.9 million in 2021 frame the typical range for Net Equity Issued and Repurchased.
- Peak annual rise in Net Equity Issued and Repurchased reached 470.21% in 2021, while the deepest fall reached 252.06% in 2021.
- Tracing EYPT's Net Equity Issued and Repurchased over 4 years: stood at -$7.3 million in 2021, then jumped by 3243.36% to $230.0 million in 2023, then slumped by 34.12% to $151.5 million in 2024, then rose by 10.08% to $166.8 million in 2025.
- Business Quant data shows EYPT's Net Equity Issued and Repurchased at $166.8 million in Q4 2025, $6.9 million in Q3 2025, and $151.5 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 166.79 Mn |
| Dec 31, 2025 | 166.79 Mn |
| Sep 30, 2025 | 6.90 Mn |
| Sep 30, 2025 | 6.90 Mn |
| Dec 31, 2024 | 151.52 Mn |
| Dec 31, 2024 | 151.52 Mn |
| Sep 30, 2024 | 12.20 Mn |
| Sep 30, 2024 | 12.20 Mn |
| Dec 31, 2023 | 230.00 Mn |
| Dec 31, 2023 | 230.00 Mn |
| Sep 30, 2021 | -7.32 Mn |
| Sep 30, 2021 | -7.32 Mn |
| Jun 30, 2021 | -1,000.00 |
| Jun 30, 2021 | -1,000.00 |
| Mar 31, 2021 | 115.67 Mn |
| Mar 31, 2021 | 115.67 Mn |
| Dec 31, 2020 | 25.12 Mn |
| Dec 31, 2020 | 25.12 Mn |
| Sep 30, 2020 | 4.81 Mn |
| Sep 30, 2020 | 4.81 Mn |